Evidence map›Paper›PMID 38077815›Full record

ArticleResearch and practice in thrombosis and haemostasis2023

Ethical aspects of hemophilia gene therapy: a qualitative interview study with stakeholders.

Lieke Baas, Karina Meijer, Mariëtte Driessens, Annelien L Bredenoord, Rieke van der Graaf, SYMPHONY consortium@SYMPHONY_NL, SYMPHONY consortium

Open access · goldAbstract read
In one paragraph

Article in Research and practice in thrombosis and haemostasis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.5field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Can hemophilia be cured? It depends on the definition.Research and practice in thrombosis and haemostasis · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 1 country.

Lieke BaasDepartment of Bioethics and Health Humanities, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
Karina MeijerDepartment of Hematology, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
Mariëtte DriessensNetherlands Hemophilia Patients Society (NVHP), Nijkerk, The Netherlands.
Annelien L BredenoordErasmus School of Philosophy, Erasmus University Rotterdam, Rotterdam, The Netherlands.
Rieke van der GraafDepartment of Bioethics and Health Humanities, Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, The Netherlands.
SYMPHONY consortium@SYMPHONY_NL
SYMPHONY consortium
University Medical Center Utrecht · NLDutch Cancer Society · NLErasmus University Rotterdam · NLUniversity of Groningen · NLUtrecht University · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: There are great expectations for the potential role of gene therapy in the treatment of hemophilia. At the same time, developments in the field of hemophilia gene therapy have always raised ethical issues. It remains unknown how these ethical issues are perceived by stakeholders, particularly regarding the most recent developments in the field. Objectives: To obtain insight into stakeholders' morally reasoned opinions on gene therapy for hemophilia. Methods: We conducted qualitative research with Dutch people with hemophilia ( Results: We identified 3 main themes. The theme Conclusion: Stakeholders embrace the theoretical potential of gene therapy, while several people with hemophilia question the added value of the current gene transfer products for themselves.

Indexed as

ethicsfreedomgene therapyhemophiliaqualitative research

Identifiers

PMID38077815
PMCPMC10704513
OpenAlexW4387776429

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.